Bicara Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $1.19B
- P/E (TTM)
- –
- Dividend yield
- –
About Bicara Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical firm developing bifunctional therapies for patients with solid tumors. Its platform combines tumor-targeting antibodies with modulating agents to deliver localized treatment within the tumor microenvironment. The lead product candidate, ficerafusp alfa, is a bifunctional antibody designed to inhibit epidermal growth factor receptors while neutralizing transforming growth factor beta. This therapy primarily targets head and neck squamous cell carcinomas, alongside other solid tumors such as colorectal, cutaneous squamous cell, and anal squamous cell cancers. The company serves patients with advanced, recurrent, or metastatic solid malignancies.
Regarding scale and geography, the company conducts international clinical development, highlighted by an ongoing global Phase 2/3 pivotal trial enrolling approximately 650 patients. It also runs multiple Phase 1b expansion cohorts and maintains commercial relationships with Biocon Limited and MSD International. The excerpt does not disclose the company's headquarters or specific geographic facility locations.
Summary of the business section of Bicara Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bicara Therapeutics Inc.
- Headquarters
- Boston, MA
- Address
- 116 Huntington Avenue Suite 703 02116
- Phone
- (617) 468-4219
- Website
- bicara.com
- Employees
- 103, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- BCAX
- Exchange
- Nasdaq
- IPO date
- Sep 13, 2024
- Shares outstanding
- 66M, Aug 6, 2026
- Public float
- $376.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2023658
- CUSIP
- 055477103
- ISIN
- US0554771032
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan Cohlhepp | President, COO & Interim CEO, Director | 199,141 |
| Claire Mazumdar | Chief Executive Officer, Director | 372,152 |
| Jennifer Larson | Chief Financial Officer | – |
| Ivan Hyep | Chief Financial Officer | 129,855 |
| William Schelman | Chief Medical Officer | – |
| David Raben | Chief Medical Officer | 60,786 |
| Lara Meisner | Chief Legal Officer | 0 |
| Christy J. Oliger | Director | – |
| Jeremy Bender | Director | – |
| Rajeev M. Shah | Director | – |
| Kate Haviland | Director | 7,437 |
| Michael Powell | Director | – |
| Christopher Bowden | Director | – |
| Jake Simson | Director | – |
| Scott M. Robertson | Director | – |
| Kiran Mazumdar-Shaw | Director | 6,297,854 |
| Capital Healthcare Fund LP RA | Director | – |
| Ra Capital Management, L.P. | Director | 4,603,418 |
| Peter Kolchinsky | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | 2,622,898 |
| Nils Lonberg | Director | 29,991 |
Employees
Headcount reported in annual reports
“As of March 24, 2026, we had 103 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 10, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |